Lin-Xian Li
Co-Founder & Chief Executive Officer Innorna
Seminars
Wednesday 8th April 2026
Innorna: Engineering Targeted mRNA-LNPs to Advance In Vivo Immunotherapy
4:30 pm
- Introducing Innorna: Company overview, pipeline programs, and platform technologies
- Case study: Advancing in vivo immunotherapy through targeted mRNA-LNP engineering
- Exploring opportunities with Innorna’s pipeline and platform across diverse therapeutic areas
NEW DATA
